trending Market Intelligence /marketintelligence/en/news-insights/trending/Wy72IcqNOInSYJcntYNAkA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

AbbVie's rheumatoid arthritis drug Rinvoq wins EU approval

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

AbbVie's rheumatoid arthritis drug Rinvoq wins EU approval

The European Commission approved North Chicago, Ill.-based AbbVie Inc.'s Rinvoq for the treatment of certain adult rheumatoid arthritis patients.

The regulator approved Rinvoq, or upadacitinib, to treat adult patients with moderate to severe active rheumatoid arthritis who cannot take or have responded inadequately to one or more disease-modifying anti-rheumatic drugs.

Rheumatoid arthritis is an autoimmune disease affecting about 23.7 million people worldwide. It occurs when the immune system mistakenly attacks its own tissue, causing pain, swelling and bone erosion.

The approval was supported by a 4,400-patient phase 3 Select program, in which the drug achieved all primary goals, with a higher percentage of patients experiencing almost no symptoms and disease activity after being treated with the drug.

Earlier in August, the U.S. Food and Drug Administration approved Rinvoq for the same indication.